ArticleJournal of advanced pharmaceutical technology & research2014
In vitro evaluation of anticancer potentials of lupeol isolated from Elephantopus scaber L. on MCF-7 cell line.
Article in Journal of advanced pharmaceutical technology & research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 82 citations in OpenAlex.
- Exploiting signal transduction pathways for cancer therapy: insights from natural products in preclinical models.Frontiers in pharmacology · 2026Review
- Review
- Enhancing the Pharmacological Properties of Triterpenes Through Acetylation: An Anticancer and Antioxidant Perspective.Molecules (Basel, Switzerland) · 2025Article
- An updated review deciphering the anticancer potential of pentacyclic triterpene lupeol and its nanoformulations.Frontiers in pharmacology · 2025Review
- Current Insights into Therapeutic Potential of Terpenoids as Anticancer Agents.Anti-cancer agents in medicinal chemistry · 2025Review
- The Emerging Role of Natural Products in Cancer Treatment.Archives of toxicology · 2024Review
- Preparation, characterization and antioxidant and anticancerous potential of Quercetin loaded β-glucan particles derived from mushroom and yeast.Scientific reports · 2024Article
- Unraveling the Impact of Six Pentacyclic Triterpenes Regulating Metabolic Pathways on Lung Carcinoma Cells.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Review
- Lupeol and Paclitaxel cooperate in hindering hypoxia induced vasculogenic mimicry via suppression of HIF-1α-EphA2-Laminin-5γ2 network in human oral cancer.Journal of cell communication and signaling · 2023Article
- Valorization of Bioactive Compounds from By-Products ofPlants (Basel, Switzerland) · 2023Article
- Lupeol synergizes with doxorubicin to induce anti-proliferative and apoptotic effects on breast cancer cells.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2022Article
- Article
- Molecular docking analysis of lupeol with different cancer targets.Bioinformation · 2022Article
- Normal breast epithelial MCF-10A cells to evaluate the safety of carbon dots.RSC medicinal chemistry · 2021Article
- Phytochemical Constituents ofBiomolecules · 2021Article
- Synergistic Cytotoxicity betweenEvidence-based complementary and alternative medicine : eCAM · 2021Article
- Brazilian Red Propolis: Extracts Production, Physicochemical Characterization, and Cytotoxicity Profile for Antitumor Activity.Biomolecules · 2020Article
- Plant triterpenoid saponins: biosynthesis, in vitro production, and pharmacological relevance.Protoplasma · 2019Review
- Anticancer activity and concurrent analysis of ursolic acid, β-sitosterol and lupeol in three differentSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
unlabelledLupeol is a triterpenoid, present in most of the medicinally effective plants and possess a wide range of biological activity against human diseases. The present study aims at evaluating the anticancer potentials of lupeol, isolated from the leaves of Elephantopus scaber L. and thereby explores its action on key cancer marker, Bcl-2. The effect of lupeol on the cell viability of MCF-7 was determined by MTT and lactate dehydrogenase assays at different concentrations. The efficacy of the compound to induce cell death was analyzed using AO/EtBr staining. Phase contrast microscopic analysis provided the changes in cell morphology of the compound treated normal breast cells (MCF-10A) and MCF-7 cells. The expression of Bcl-2 and Bcl-xL proteins in the normal, cancer and lupeol treated cancer cell was analyzed by western blotting. Lupeol induced an effective change in the cell viability of MCF-7 cells with IC50 concentration as 80 μM. Induction of cell death, change in cell morphology and population of the cancer cells was observed in the lupeol treated cells, but the normal cells were not affected. The compound effectively downregulated Bcl-2 and Bcl-xL protein expressions, which directly contribute for the induction of MCF-7 cell apoptosis.
conclusionThus, lupeol acts as an anticancer agent against MCF-7 cells and is a potent phytodrug to be explored further for its cytotoxic mechanism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.